Related Experiment Video
Updated: Jul 9, 2025

12:10
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
7.8K
Three-dimensional automatic artificial intelligence driven augmented-reality selective biopsy during nerve-sparing
Enrico Checcucci1, Alberto Piana2, Gabriele Volpi1
1Department of Surgery, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
Asian Journal of Urology
|November 29, 2023
Summary
This study shows that a new AI-powered 3D augmented reality system accurately identifies prostate cancer on the neurovascular bundle, enabling nerve-sparing surgery even in advanced cases.
Area of Science:
- Urology
- Surgical Oncology
- Medical Imaging
Background:
- Robot-assisted radical prostatectomy (RARP) aims for cancer removal while preserving neurovascular bundles (NVBs).
- Accurate intraoperative localization of tumors near NVBs is crucial for nerve sparing and oncological control.
- Existing methods may have limitations in precisely identifying tumor extent at the NVB level.
Purpose of the Study:
- To evaluate the accuracy of a novel 3D artificial intelligence (AI)-driven automatic augmented reality (AAR) system.
- To assess the system's ability to identify tumor location at the NVB during RARP.
- To determine the impact of this technology on surgical outcomes.
Main Methods:
- Prospective study of 34 prostate cancer patients (cT1c-3, cN0, cM0) undergoing RARP.
- Preoperative multiparametric MRI used to assess capsular contact or extracapsular extension.
- AI-driven 3D AAR system employed at the end of the extirpative phase to guide selective biopsies of the NVB.
Main Results:
- The 3D AAR system identified tumor location on the NVB in 87.5% of pT3 patients.
- Positive surgical margin (PSM) rates were 0% for pT2 and 7.1% for pT3 cases.
- The system facilitated tailored nerve-sparing surgery in locally advanced disease.
Conclusions:
- The AI-driven 3D AAR system accurately localizes tumors at the NVB in RARP.
- This technology allows for precise nerve-sparing surgery, even in locally advanced prostate cancer.
- Oncological safety, measured by PSM rates, is maintained with this advanced system.

